Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates

Epithelial ovarian cancers are largely comprised of immunogenic tumor sub-types with the degree of CD8+ T cell infiltration being prognostic of clinical outcome. Tumor antigen-specific T cells are identified among these infiltrating T cell populations which has spurred a decade of development towards antigen-specific immunotherapies. Despite these efforts, the success of such immunotherapies has shown to be limited. In this study, we used state-of-the art immunopeptidomics approach and a novel proteogenomic profiling method to identify potential immunogenic human leukocyte antigen class I-presented peptides from patient-derived high-grade serous ovarian cancer. From 11 patients' tumors, we identified promising candidates for their therapeutic potential. Of these, we selected the best 13 candidates and validated their immunogenicity in both healthy donors and cancer patients.

Authors

Institutions

Publication Details

Journal
npj Vaccines
Published
2025-08-16
DOI
https://doi.org/10.1038/s41541-025-01234-6
Citations
1
Primary Topic
vaccines and immunoinformatics approaches
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates

Kadri Õunap, Sara Wojciechowski, Olga L. Gurvich, Vincenzo Cerullo et al.
1 citations
npj Vaccines
vaccines and immunoinformatics approaches
0.81
article

Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates

Kadri Õunap, Sara Wojciechowski, Olga L. Gurvich, Vincenzo Cerullo, Tuija Kekarainen, Karita Peltonen, Salvatore Russo, Félix Elortza, Aubrey Bailey, Sara Feola, Jacopo Chiaro, Masoumeh Es-Haghi, Mikel Azkargorta, Hanna Sallinen, Maarit Anttila
article en
1 citations

Abstract

Epithelial ovarian cancers are largely comprised of immunogenic tumor sub-types with the degree of CD8+ T cell infiltration being prognostic of clinical outcome. Tumor antigen-specific T cells are identified among these infiltrating T cell populations which has spurred a decade of development towards antigen-specific immunotherapies. Despite these efforts, the success of such immunotherapies has shown to be limited. In this study, we used state-of-the art immunopeptidomics approach and a novel proteogenomic profiling method to identify potential immunogenic human leukocyte antigen class I-presented peptides from patient-derived high-grade serous ovarian cancer. From 11 patients' tumors, we identified promising candidates for their therapeutic potential. Of these, we selected the best 13 candidates and validated their immunogenicity in both healthy donors and cancer patients.

npj VaccinesVol. 10(1)
University of Helsinki (FI), Ferring Pharmaceuticals (Switzerland) (CH), Kuopio University Hospital (FI), CIC bioGUNE (ES)
Helsingin Yliopisto, Suomen Kulttuurirahasto, Jane ja Aatos Erkon Säätiö, Kuopion Yliopistollinen Sairaala, Magnus Ehrnroothin Säätiö, K. Albin Johanssons Stiftelse, Syöpäsäätiö, Horizon 2020 Framework Programme, Helsinki Institute of Life Science, Helsingin Yliopisto
Good health and well-being
Openalex Percentile: Top 25%
vaccines and immunoinformatics approaches
0.81
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.